More than a century ago, scientists who discovered insulin dreamed of an accessible treatment for all people with diabetes.They sold the patent for only 1 dollar, less than 1 euro at the time, hoping that it would never be uninquerable.However, today only half of those who need insulin in the world can access it.This situation, as Dr. Helen Bygrave of the MSF access campaign points out, demonstrates how the system has failed to offer fair and equitable access.
Insulin Pen: An improvement in the quality of life
Insulin pens were developed to facilitate diabetes control, offering a precise dosage, comfort and less stigma compared to traditional syringes.In addition, these devices are included in the WHO essential medication model list.A MSF and T1international survey showed that 82% of people with diabetes prefer pens, but, despite their advantages, they remain inaccessible and expensive for millions of people, especially in low and medium income countries.
An affordable price is possible
According to recent Jama Network Open data, a human insulin pen could be sold at an estimated generic price of 0.88 euros, still generating a profit margin.However, current prices vary drastically between countries: 1.87 euros in South Africa, 5.43 euros in India, 13.17 euros in the Philippines and up to 85.31 euros in the United States.This double standard in access to insulin by pharmaceutical companies such as Eli Lilly, Novo Nordisk and Sanofi leaves millions without the necessary treatment to lead a healthy life.
We need a change!
Ensure that all people with diabetes can access insulin pens at an accessible price is a matter of public rights and health.If we manage to reduce prices and increase supply, millions of people will be able to receive the treatment they deserve without facing economic barriers.
From here, we call companies and governments to commit to a change in access to insulin, achieving a true impact on the lives of those who live with diabetes.💙
In this month of November, where we will celebrate World Diabetes Day, do you think it is fair that a really affordable type of insulin has not yet been achieved for everyone?
Greetings,
